Pharmacogenomics in inflammatory bowel disease

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 1, 2006, Pages 21-28

  Egan, Laurence J ^a,d   Derijks, Luc J J ^b   Hommes, Daniel W ^c  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b MÁXIMA MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALLOPURINOL; AZATHIOPRINE; CAPTOPRIL; CISAPRIDE; CODEINE; COTRIMOXAZOLE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; GEFITINIB; GUANOSINE PHOSPHATE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INORGANIC PYROPHOSPHATASE; INOSINE TRIPHOSPHATE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; MORPHINE; OMEPRAZOLE; SYNTHETASE; TERFENADINE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; WARFARIN; XENOBIOTIC AGENT;

ALLELE; BONE MARROW SUPPRESSION; CROHN DISEASE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSFORMATION; ENTERITIS; GENE SEQUENCE; GENETIC TRAIT; GENETIC VARIABILITY; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LEUKOPENIA; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TORSADE DES POINTES; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 31144434861     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2005.10.003     Document Type: Article

References (57)

1. E.S. Vesell Pharmacogenetic perspectives gained from twin and family studies Pharmacol Ther 41 1989 535 552
2. W. Kalow Pharmacogenetics heredity and the response to drugs 1962 WB Saunders Philadelphia
3. D.A. Price Evans Genetic factors in drug therapy clinical and molecular pharmacogenetics 1993 Cambridge University Press New York
4. R. Weinshilboum Inheritance and drug response N Engl J Med 348 2003 529 537
5. R. Weinshilboum, L. Wang Pharmacogenetics inherited variation in amino acid sequence and altered protein quantity Clin Pharmacol Ther 75 2004 253 258
6. J.A. Goldstein, T. Ishizaki, K. Chiba Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations Pharmacogenetics 7 1997 59 64
7. R.B. Kim, B.F. Leake, E.F. Choo Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 2001 189 199
8. W.E. Evans, H.L. McLeod Pharmacogenomics drug disposition, drug targets, and side effects N Engl J Med 348 2003 538 549
9. A. Ullrich, L. Coussens, J.S. Hayflick Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells Nature 309 1984 418 425
10. T.A. Libermann, H.R. Nusbaum, N. Razon Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin Nature 313 1985 144 147
11. R. Sordella, D.W. Bell, D.A. Haber Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 2004 1163 1167
12. J.G. Paez, P.A. Janne, J.C. Lee EGFR mutations in lung cancer correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
13. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
14. S. Mohammad, Z. Zhou, Q. Gong Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride Am J Physiol 273 1997 H2534 H2538
15. G.W. Abbott, F. Sesti, I. Splawski MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia Cell 97 1999 175 187
16. D.J. Adler, B.I. Korelitz The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis Am J Gastroenterol 85 1990 717 722
17. D.C. Pearson, G.R. May, G.H. Fick Azathioprine and 6-mercaptopurine in Crohn disease a meta-analysis Ann Intern Med 123 1995 132 142
18. W.J. Sandborn A review of immune modifier therapy for inflammatory bowel disease azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate Am J Gastroenterol 91 1996 423 433
19. B.I. Korelitz, D.J. Adler, R.A. Mendelsohn Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease Am J Gastroenterol 88 1993 1198 1205
20. L. Lennard The clinical pharmacology of 6-mercaptopurine Eur J Clin Pharmacol 43 1992 329 339
21. E. Schaeffeler, T. Lang, U.M. Zanger High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC Clin Chem 47 2001 548 555
22. E. Schaeffeler, C. Fischer, D. Brockmeier Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants Pharmacogenetics 14 2004 407 417
23. L. Yan, S. Zhang, B. Eiff Thiopurine methyltransferase polymorphic tandem repeat genotype-phenotype correlation analysis Clin Pharmacol Ther 68 2000 210 219
24. S. Alves, A. Amorim, F. Ferreira Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity Clin Pharmacol Ther 70 2001 165 174
25. H.L. Tai, E.Y. Krynetski, E.G. Schuetz Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT* (*)3A, TPMT* (*)2) mechanisms for the genetic polymorphism of TPMT activity Proc Natl Acad Sci U S A 94 1997 6444 6449
26. L.O. Reuther, J. Sonne, N. Larsen Thiopurine methyltransferase genotype distribution in patients with Crohn's disease Aliment Pharmacol Ther 17 2003 65 68
27. C.R. Yates, E.Y. Krynetski, T. Loennechen Molecular diagnosis of thiopurine S-methyltransferase deficiency genetic basis for azathioprine and mercaptopurine intolerance Ann Intern Med 126 1997 608 614
28. A. Ansari, C. Hassan, J. Duley Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease Aliment Pharmacol Ther 16 2002 1743 1750
29. M. Kurzawski, B. Gawronska-Szklarz, M. Drozdzik Frequency distribution of thiopurine s-methyltransferase alleles in a Polish population Ther Drug Monit 26 2004 541 545
30. T. Kubota, K. Chiba Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT* (*)2, * (*)3A, * (*)3B and * (*)3C) in 151 healthy Japanese subjects and the inheritance of TPMT* (*)3C in the family of a propositus Br J Clin Pharmacol 51 2001 475 477
31. M.M. Ameyaw, E.S. Collie-Duguid, R.H. Powrie Thiopurine methyltransferase alleles in British and Ghanaian populations Hum Mol Genet 8 1999 367 370
32. E.S. Collie-Duguid, S.C. Pritchard, R.H. Powrie The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations Pharmacogenetics 9 1999 37 42
33. J. Sanderson, A. Ansari, T. Marinaki Thiopurine methyltransferase should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem 41 2004 294 302
34. L. Lennard TPMT in the treatment of Crohn's disease with azathioprine Gut 51 2002 143 146
35. R.M. Weinshilboum, S.L. Sladek Mercaptopurine pharmacogenetics monogenic inheritance of erythrocyte thiopurine methyltransferase activity Am J Hum Genet 32 1980 651 662
36. B. Pettersson, S. Almer, F. Albertioni Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy possible role of concomitant methotrexate Ther Drug Monit 24 2002 351 358
37. D. Indjova, S. Atanasova, M. Shipkova Phenotypic and genotypic analysis of thiopurine s-methyltransferase polymorphism in the Bulgarian population Ther Drug Monit 25 2003 631 636
38. J.H. Fraser, H. Meyers, J.F. Henderson Individual variation in inosine triphosphate accumulation in human erythrocytes Clin Biochem 8 1975 353 364
39. A.M. Marinaki, A. Ansari, J.A. Duley Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase) Pharmacogenetics 14 2004 181 187
40. S. Sumi, A.M. Marinaki, M. Arenas Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency Hum Genet 111 2002 360 367
41. E.Y. Krynetski, W.E. Evans Genetic polymorphism of thiopurine S-methyltransferase molecular mechanisms and clinical importance Pharmacology 61 2000 136 146
42. E.Y. Krynetski, J.D. Schuetz, A.J. Galpin A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase Proc Natl Acad Sci U S A 92 1995 949 953
43. J.A. Duley, H.A. Simmonds, D.A. Hopkinson Inosine triphosphate pyrophosphohydrolase deficiency in a kindred with adenosine deaminase deficiency Clin Chim Acta 188 1990 243 252
44. M.C. Dubinsky, S. Lamothe, H.Y. Yang Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease Gastroenterology 118 2000 705 713
45. A.J. Black, H.L. McLeod, H.A. Capell Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine Ann Intern Med 129 1998 716 718
46. S. Campbell, K. Kingstone, S. Ghosh Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine Aliment Pharmacol Ther 16 2002 389 398
47. J.F. Colombel, N. Ferrari, H. Debuysere Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy Gastroenterology 118 2000 1025 1030
48. R.B. Gearry, M.L. Barclay, M.J. Burt Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease Aliment Pharmacol Ther 18 2003 395 400
49. M. Regueiro, H. Mardini Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease J Clin Gastroenterol 35 2002 240 244
50. W.J. Sandborn Rational dosing of azathioprine and 6-mercaptopurine Gut 48 2001 591 592
51. E.G. Seidman Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD Rev Gastroenterol Disord 3 Suppl 1 2003 S30 S38
52. B.A. Kaskas, E. Louis, U. Hindorf Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine Gut 52 2003 140 142
53. J.M. Dupret, F. Rodrigues-Lima Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases Curr Med Chem 12 2005 311 318
54. K.P. Vatsis, W.W. Weber, D.A. Bell Nomenclature for N-acetyltransferases Pharmacogenetics 5 1995 1 17
55. E. Ricart, W.R. Taylor, E.V. Loftus N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis Am J Gastroenterol 97 2002 1763 1768
56. R.A. Cartwright, R.W. Glashan, H.J. Rogers Role of N-acetyltransferase phenotypes in bladder carcinogenesis a pharmacogenic epidemiological approach to bladder cancer Lancet 16 1982 842 845
57. R. Weinshilboum, L. Wang Pharmacogenomics bench to bedside Nat Rev Drug Discov 3 2004 739 748